Ying Lu

Ying Lu

Auto-generated profile, based on publicly available information

Ying Lu

Department of Radiation Oncology Hubei Cancer Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2026 in Precision Radiation Oncology
Verified
Journal Article
Open access
YLYing Lu
Ying Lu
YWYoujia Wang
Youjia Wang
GHGuang Han
Guang Han
JBJianping Bi
Jianping Bi
GPGuoliang Pi
Guoliang Pi
YLYing Li
Ying Li
Objective: Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively investigated to improve clinical outcomes; however, this strategy may also increase the risk of treatment‐related toxicities. This multicenter study aimed to identify clinical and dosimetric predictors of treatment‐related pneumonitis (TRP) in this patient population, focusing on modifiable predictors of toxicity. Methods: A retrospective review was conducted on 69 patients with lung or esophageal cancer treated at three hospitals. All patients received concurrent ICIs, chemotherapy, and thoracic radiotherapy at a dose of 50–60 Gy (in 2 Gy fractions) using inverse‐planned techniques. TRP was graded according to the Common Terminology Criteria for Adverse Events version 5.0. Logistic regression modeling and receiver operating characteristic (ROC) analysis were employed for statistical evaluation. Results: Any‐grade TRP occurred in 56.5% of patients. Grade 2–5 TRP occurred in 30.4%, 8.7%, 1.4%, and 0% of patients, respectively. Age ( p  = 0.01; OR  = 1.1) and mean lung dose (MLD) ( p  = 0.02; OR  = 2.4) independently contributed to the risk of any‐grade TRP. Age ( p  = 0.03; OR  = 1.1) and MLD ( p  = 0.04; OR  = 1.7) were also identified as risk factors for grade 2+ TRP. Other parameters, such as lung V 5, V 10, V 15, V 20, and V 30 were not significantly associated with TRP. ROC analysis identified 13.6 Gy as the optimal MLD threshold for predicting both any‐grade and grade 2+ TRP. Conclusions: MLD and age were associated with a higher risk of TRP in patients receiving concurrent chemoradiotherapy and ICIs. These findings may help inform revisions to lung dose constraints, although validation in large‐scale prospective trials is warranted.